Scott Gottlieb
InvestorSpecial Partner at New Enterprise Associates (NEA)
Chevy Chase, Maryland
Writes $2M – $50M checks · typically $25M
About
Scott Gottlieb is a physician and policy expert who joined NEA's healthcare investment team as a Special Partner in 2019, having previously been a Venture Partner at the firm from 2007 to 2017. Between those roles he served as the 23rd Commissioner of the U.S. Food and Drug Administration (2017–2019), and earlier held positions as FDA Deputy Commissioner and Senior Adviser at the Centers for Medicare and Medicaid Services. He was a practicing hospitalist and Clinical Assistant Professor at NYU School of Medicine, is a graduate of Mount Sinai School of Medicine and Wesleyan University, and at NEA focuses on healthcare investing with an emphasis on biopharma and healthcare services.
Invests in
AI & Machine LearningBiotechDigital HealthHealthtechMedical Devices
Experience
- New Enterprise AssociatesPartnercurrent2007 — presentChevy Chase, MD
- American Enterprise InstituteSenior Fellowcurrent2003 — presentWashington D.C. Metro Area
- National Academy of MedicineElected Membercurrent2018 — presentWashington D.C. Metro Area
- PfizerIndependent Member of the Board of Directorscurrent2019 — presentBoston, MA
- UnitedHealth GroupIndependent Member of the Board of Directorscurrent2025 — presentMinnesota, United States
- IlluminaChairman of the Board of Directorscurrent2020 — presentSan Diego, California, United States
- Xaira TherapeuticsBoard Membercurrent2024 — presentSan Francisco, California, United States
- Comanche BiopharmaBoard Membercurrent2024 — presentBoston, Massachusetts, United States
- ResilienceBoard Membercurrent2020 — presentBoston, Massachusetts, United States
- AetionBoard Membercurrent2019 — presentNew York, United States
- Tempus AIIndependent Member of the Board of Directorscurrent2019 — presentChicago, Illinois, United States
- FDACommissioner2017 — 2019White Oak, MD
- U.S. Department of Health and Human Services (HHS)Member Federal Health IT Policy Committee2013 — 2017Washington, DC
- Society of Hospital MedicineMember of the Policy Board2011 — 2017
- Daiichi Sankyo, Inc.Independent Member of the Board of Directors2015 — 2017Livingston, NJ
- American Pathology PartnersIndependent Member of the Board of Directors2012 — 2017Denver, CO
- NYU Langone HealthClinical Assistant Professor2011 — 2017New York, NY
- GlaxoSmithKlineMember of the Product Investment Board2010 — 2017Greater Philadelphia Area
- Gradalis, Inc.Independent Member of the Board of Directors2015 — 2017Dallas, TX
- MedAvanteIndependent Member of the Board of Directors2007 — 2017Princeton, NJ
Education
- Icahn School of Medicine at Mount SinaiResident, Internal Medicine Residency Program1999 — 2002
- Icahn School of Medicine at Mount SinaiDoctor of Medicine (MD), Medicine1995 — 1999
- Wesleyan UniversityBA, Economics1990 — 1994
Skills & more
+12 more
NonprofitsStrategyPublic HealthPublic SpeakingCoalitionsResearchGovernmentLegislative RelationsPolicyPublic RelationsPoliticsMedicineFrom Scott's professional profile.
Same school
Also attended Icahn School of Medicine at Mount Sinai15
+ 9 more
Also attended Wesleyan University59
+ 53 more
Shared employers
Also worked at American Enterprise Institute6
Also worked at National Academy of Medicine3
Also worked at Xaira Therapeutics7
+ 1 more
Also worked at Tempus AI10
+ 4 more
Deals · 1
Tempus LabsBoard seat
via New Enterprise Associates (NEA) · filed Oct 2022 · $10M raise
Attribution from SEC filings, press coverage, and firm rosters.






































